Keywords: ایداروبیسین; Cladribine; Cytarabine; Idarubicin; Acute myeloid leukemia; Induction chemotherapy; Leukemia risk; NCCN; ELN; Anthracycline; Risk prediction; Prognosis; AML;
مقالات ISI ایداروبیسین (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ایداروبیسین; Anthracycline; Daunorubicin; Idarubicin; Mitoxantrone; Acute myeloid leukemia; Heart failure; Cardiotoxicity;
Keywords: ایداروبیسین; Grape seed proanthocyanidins; Free radicals; DNA damage; Apoptosis; Necrosis; Multiorgan toxicity; Cancer; Vitamins C, E and β-carotene; Idarubicin; 4-Hydroxyperoxycyclophosphamide; Amiodarone; Doxorubicin; Dimethylnitrosamine
Keywords: ایداروبیسین; Idarubicin; Folic acid; Polyethylene glycol (PEG); Magnetic nanoparticle; Drug delivery; MCF-7
Keywords: ایداروبیسین; Idarubicin; Daunorubicin; Acute leukemia;
Keywords: ایداروبیسین; Idarubicin; FTIR spectroscopy; UV-vis spectroscopy; Intercalation; Circular dichroism spectroscopy; Protein data bank;
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)
Keywords: ایداروبیسین; Acute myeloid leukemia; Relapsed; Refractory; Pravastatin; Idarubicin; Cytarabine;
Specific delivery of idarubicin to HER2-positive breast cancerous cell line by trastuzumab-conjugated liposomes
Keywords: ایداروبیسین; Idarubicin; Liposome; Anti-HER2 immunoliposome; Chemotherapy; Specific targeting; Breast cancer;
Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial
Keywords: ایداروبیسین; Hepatocellular carcinoma; Idarubicin; Chemolipiodolisation; Phase I;
Original articleDNA damage induced by NADPH cytochrome P450 reductase-activated idarubicin in sensitive and multidrug resistant MCF7 breast cancer cells
Keywords: ایداروبیسین; Anthracycline antitumour drugs; Idarubicin; NADPH cytochrome P450 reductase; Multidrug resistance; DNA damage;
How can one optimize induction therapy in AML?
Keywords: ایداروبیسین; Acute myeloid leukemia; AML; Ara-C; Azacitidine; Induction; Cladribine; Clofarabine; CPX-351; Cytarabine; Daunorubicin; Etoposide; Fludarabine; Gemtuzumab ozogamicin; Idarubicin; Vadastuximab talirine;
Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study
Keywords: ایداروبیسین; allo-HSCT; allogeneic hematopoietic stem cell transplantation; IDA; idarubicin; AML; acute myeloid leukemia; ALL; acute lymphocytic leukemia; OS; overall survival; DFS; disease-free survival; RR; relapse rate; BU; busulfan; CY; cyclophosphamide; VP-16; et
Pentoxifylline affects idarubicin binding to DNA
Keywords: ایداروبیسین; BACs; biologically active aromatic compounds; IDA; Idarubicin; PTX; pentoxifylline; Stacking complexes; Hetero-aggregation; Methylxanthines; Flow cytometry; Ames test;
l-Cysteine capped Mn-doped ZnS quantum dots as a room temperature phosphorescence sensor for in-vitro binding assay of idarubicin and DNA
Keywords: ایداروبیسین; l-cysteine capped Mn doped ZnS quantum dots; Room temperature phosphorescence sensor; DNA; Idarubicin; DNA binding;
Comparison of outcomes of idarubicin intensified TBI-CY and traditional TBI-CY conditioning regimen for high-risk acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A single center experience
Keywords: ایداروبیسین; ALL; acute lymphoblastic leukemia; allo-HSCT; allogeneic hematopoietic stem cell transplantation; TRM; transplant-related mortality; IDA; idarubicin; HR; hazard ratio; CI; confidence interval; NR; no remission; TBI; total body irradiation; CY; cyclophosph
Formulation and optimization of idarubicin thermosensitive liposomes provides ultrafast triggered release at mild hyperthermia and improves tumor response
Keywords: ایداروبیسین; Idarubicin hydrochloride (PubChem CID: 636,362); DPPC (PubChem CID: 160,339); DSPC (PubChem CID: 94,190); DSPE-PEG (PubChem CID: 86,278,269); Diammonium EDTA (PubChem CID: 13,847,684); Diammonium sulfate (PubChem CID: 6,097,028); Diammonium oxalate (PubCh
Management of persistent AML at day 14
Keywords: ایداروبیسین; acute myeloid leukemia; allogeneic hematopoietic cell transplantation; ara-C; AML; cytarabine; daunorubicin; day 14; HCT; HiDAC; high-dose ara-C; idarubicin; multiparameter flow cytometry; MPFC; persistence
Redox mechanism of anticancer drug idarubicin and in-situ evaluation of interaction with DNA using an electrochemical biosensor
Keywords: ایداروبیسین; Idarubicin; Electrochemical biosensor; Drug–DNA interaction; Oxidation; Voltammetry
In vitro DNA binding studies of anticancer drug idarubicin using spectroscopic techniques
Keywords: ایداروبیسین; DNA; Idarubicin; Ethidium bromide; DNA binding; Spectrofluorometry; Spectrophotometry
A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia
Keywords: ایداروبیسین; AML; acute myeloid leukemia; DLT; dose-limiting toxicity; DSMC; Data Safety Monitoring Committee; EMSA; electrophoretic mobility shift assay; FACS; fluorescence-activated cell sorting; iKBa; inhibitor of NF-kB; LSC; leukemic stem cell; MDS; myelodysplasti
Characterization of degradation products of idarubicin through LC-UV, MSn and LC-MS-TOF studies
Keywords: ایداروبیسین; Idarubicin; Forced degradation; LC-MS-TOF; Degradation product; Mass fragmentation;
HPLC quantification of doxorubicin in plasma and tissues of rats treated with doxorubicin loaded poly(alkylcyanoacrylate) nanoparticles
Keywords: ایداروبیسین; Doxorubicin; Idarubicin; Doxorubicinol; Doxorubicinon; Poly(alkylcyanoacrylate) nanoparticles
Enhanced cellular delivery of idarubicin by surface modification of propyl starch nanoparticles employing pteroic acid conjugated polyvinyl alcohol
Keywords: ایداروبیسین; Nanoparticles; Idarubicin; Cellular uptake; Protein adsorption; Cytotoxicity; Confocal scanning laser microscopy
Anthracyclines and their metabolism in human liver microsomes and the participation of the new microsomal carbonyl reductase
Keywords: ایداروبیسین; SDR; short-chain dehydrogenyse/reductase; AKR; aldo-keto reductase; 11β-HSD1; 11β-hydroxysteroid dehydrogenase 1; ANT; anthracycline; DAUN; daunorubicin; DAUNOL; daunorubicinol; ADAUN; aglycone of daunorubicin; ADAUNOL; aglycone of daunorubicinol; DOX;
Risk-Adapted Approaches to Therapy for High-Risk Acute Promyelocytic Leukemia
Keywords: ایداروبیسین; All-trans-retinoic acid; Arsenic trioxide; Cytarabine; Daunorubicin; Idarubicin; Mitoxantrone
Risk-Adapted Treatment for Low- and Intermediate-Risk Acute Promyelocytic Leukemia
Keywords: ایداروبیسین; 6-Mercaptopurine; All-trans-retinoic acid; Arsenic trioxide; Cytarabine; Idarubicin; Methotrexate
The encapsulation of idarubicin within liposomes using the novel EDTA ion gradient method ensures improved drug retention in vitro and in vivo
Keywords: ایداروبیسین; Liposomes; Idarubicin; Remote loading; Ion gradient; Drug encapsulation; Pharmacokinetics
Fluorescence anisotropy of membrane fluidity probes in human erythrocytes incubated with anthracyclines and glutaraldehyde
Keywords: ایداروبیسین; Daunorubicin; Idarubicin; Glutaraldehyde; Erythrocytes; Fluidity
Damage to the cell antioxidative system in human erythrocytes incubated with idarubicin and glutaraldehyde
Keywords: ایداروبیسین; Idarubicin; Erythrocytes; ROS; Glutathione; Phosphatidylserine exposure
Development and validation of a liquid chromatographic method for the simultaneous determination of four anthracyclines and their respective 13-S-dihydro metabolites in plasma and saliva
Keywords: ایداروبیسین; Anthracyclines; Doxorubicin; Epirubicin; Daunorubicin; Idarubicin; Doxorubicinol; Epirubicinol; Daunorubicinol; Idarubicinol; Plasma; Saliva; Liquid–liquid extraction (LLE); Liquid chromatography; Fluorescence detection; Method validation
Catalysis: The pharmaceutical perspective
Keywords: ایداروبیسین; Catalysis; Idarubicin; ST1535; Green chemistry
A comparison of the effect of anticancer drugs, idarubicin and adriamycin, on soluble chromatin
Keywords: ایداروبیسین; Adriamycin; Idarubicin; Chromatin; Histone protein; Anthracycline antibiotic
Digitoxin, at concentrations commonly found in the plasma of cardiac patients, antagonizes etoposide and idarubicin activity in K562 leukemia cells
Keywords: ایداروبیسین; Digitoxin; Etoposide; Idarubicin; Topoisomerase II; K-562
Interaction of doxorubicin and idarubicin with red blood cells from acute myeloid leukaemia patients
Keywords: ایداروبیسین; Doxorubicin; Idarubicin; Erythrocytes; Acute myeloid leukaemia;
Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: Role of BCR/ABL in therapeutic resistance
Keywords: ایداروبیسین; BCR/ABL; Leukemia; Drug resistance; DNA repair; Cell cycle; Apoptosis; Idarubicin; STI571
Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity
Keywords: ایداروبیسین; AML; acute myelogenous leukemia; AUC; area under the curve; CH; cholesterol; CHE; cholesteryl hexadecyl ether; cryo-TEM; cryo-transmission electron microscopy; DAPC; 1,2-diarachidoyl-sn-glycero-3-phosphatidylcholine; DBPC; 1,2-dibehenoyl-sn-glycero-3-phos